<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04839692</url>
  </required_header>
  <id_info>
    <org_study_id>2021P000010</org_study_id>
    <nct_id>NCT04839692</nct_id>
  </id_info>
  <brief_title>Assessment and Augmentation of Lip Appearance in Specific Study Populations</brief_title>
  <official_title>Assessment and Augmentation of Lip Appearance in Specific Study Populations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dieter Manstein, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate aging of the cutaneous changes of human skin anatomy in the lips&#xD;
      and perioral area to better understand and quantify the aging process in this, including the&#xD;
      effect of age on lip redness. Additionally, the investigators aim to test the effects of a&#xD;
      common lip augmentation procedure, hyaluronic-acid based fillers, on the appearance (volume,&#xD;
      texture and color) of aging lips, in addition to the tolerability of this procedure. It is&#xD;
      hypothesized that dermal lip fillers may decrease the redness of the lips.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 7, 2021</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Investigators will enroll 30 subjects; 15 subjects who are 18-30 years old and 15 subjects who are &gt;60 years old. Both groups will receive identical treatments.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>Standard photographs will be blindly reviewed by a physician.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Global Aesthetic Improvement Scale (GAIS)</measure>
    <time_frame>Day 1 and day 14</time_frame>
    <description>Compare Global Aesthetic Improvement Scale scores pre and post treatment to assess effectiveness of aesthetic procedure. The GAIS is a five-point scale ranging from 1= exceptional improvement, 2 = very improved patient, 3 = improved patient, 4 = unaltered patient, 5 = worsened patient.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Lip Fullness Grading Scale (LFGS)</measure>
    <time_frame>Day 1 and day 14</time_frame>
    <description>Compare Lip Fullness Grading Scale scores pre and post treatment to assess the lip volume change. This photonumeric rating scale ranges from 0 = very thin; 1 = thin; 2 = moderately thick; 3 = thick; and 4 = full. Improvement of lip volume is defined as ≥1 increase at post-treatment compared to pretreatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Wong-Baker FACES Pain Rating Scale</measure>
    <time_frame>Day 1</time_frame>
    <description>This scale will be used to record subject pain from the first insertion of dermal filler and the overall pain from the procedure. There are 6 faces ranging from 0 no hurt to 10 hurts the worst.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Lip color</measure>
    <time_frame>Day 1 and Day 14</time_frame>
    <description>All non-invasive imaging (OCT, digital and Cherry Imaging) will be compared pre and post treatment for possible effects on lip color.&#xD;
The Cherry Imaging analysis software contains distinct algorithms that process the generated three-dimensional images to calculate volume in cubic centimeters, precise color using saturation and hue, roughness detecting local variations in height/depth, and a ruler function that measures the distance between two distinct points.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Lip texture</measure>
    <time_frame>Day 1 and Day 14</time_frame>
    <description>All non-invasive imaging (OCT, digital and Cherry Imaging) will be compared pre and post treatment for possible effects on lip texture.&#xD;
The Cherry Imaging analysis software contains distinct algorithms that process the generated three-dimensional images to calculate volume in cubic centimeters, precise color using saturation and hue, roughness detecting local variations in height/depth, and a ruler function that measures the distance between two distinct points.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Lip volume</measure>
    <time_frame>Day 1 and Day 14</time_frame>
    <description>All non-invasive imaging (OCT, digital and Cherry Imaging) will be compared pre and post treatment for possible effects on lip volume.&#xD;
The Cherry Imaging analysis software contains distinct algorithms that process the generated three-dimensional images to calculate volume in cubic centimeters, precise color using saturation and hue, roughness detecting local variations in height/depth, and a ruler function that measures the distance between two distinct points.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Lip Aging</condition>
  <condition>Lip Augmentation</condition>
  <condition>Lip</condition>
  <arm_group>
    <arm_group_label>Young Caucasian females (18-30 years old)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Aged Caucasian females (&gt;60 years old)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyaluronic acid filler</intervention_name>
    <description>Hyaluronic acid filler treatment of the lips with Restylane Kysse, which is a FDA approved treatment for lip augmentation.</description>
    <arm_group_label>Aged Caucasian females (&gt;60 years old)</arm_group_label>
    <arm_group_label>Young Caucasian females (18-30 years old)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must be able and willing to provide written informed consent and comply with&#xD;
             the requirements of the study protocol;&#xD;
&#xD;
          -  In good general health, based on answers provided during the screening visit;&#xD;
&#xD;
          -  Subjects must be able to read and understand English;&#xD;
&#xD;
          -  Caucasian female;&#xD;
&#xD;
          -  Aged 18-30 years and ≥ 60 years;&#xD;
&#xD;
          -  Skin Types (Fitzpatrick Skin Phototypes I-III);&#xD;
&#xD;
               -  Smoking history is self-report.&#xD;
&#xD;
          -  Have very thin to moderately thick lips (Lip Fullness Grading Scale [LFGS] scores&#xD;
             0-2).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in another investigational drug or device clinical trial in the past 30&#xD;
             days;&#xD;
&#xD;
          -  Are pregnant or lactating;&#xD;
&#xD;
          -  Intake of hormone replacement therapy (HRT) in the past 6 months;&#xD;
&#xD;
          -  Have a history of drug or alcohol abuse or have reported habitual alcohol intake&#xD;
             greater than 2 standard drinks per day [e.g., 2 beers, 2 glasses of wine, or 2 mixed&#xD;
             drinks];&#xD;
&#xD;
          -  Presence of eczema, psoriasis, or any other skin disease on the lips or perioral skin;&#xD;
&#xD;
          -  Have birth marks, tattoos, scars, or any other disfiguration of the skin in the skin&#xD;
             area of interest;&#xD;
&#xD;
          -  Use of any anti-aging skin care products containing retinoic acid, retinol, or other&#xD;
             retinoids (e.g. tazarotene, adapalene) or estrogen on the skin area of interest in the&#xD;
             past 6 months;&#xD;
&#xD;
          -  Use of any prescription topical medication, such as corticosteroids or hydroquinone on&#xD;
             the skin area of interest in the past 6 months;&#xD;
&#xD;
          -  Have a history of photodynamic therapy treatment or any skin rejuvenation procedure on&#xD;
             the skin area of interest;&#xD;
&#xD;
          -  History of blood-clotting abnormality;&#xD;
&#xD;
          -  History of keloid formation or hypertrophic scarring;&#xD;
&#xD;
          -  Clinically significant abnormal findings or conditions which might, in the opinion of&#xD;
             the Investigator, interfere with study evaluations or pose a risk to subject safety&#xD;
             during the study;&#xD;
&#xD;
          -  Exhibits any clinical conditions or takes any medication which in the opinion of the&#xD;
             investigator may interfere with the study or pose a risk to subject safety during the&#xD;
             study;&#xD;
&#xD;
          -  Is not able to follow study protocol;&#xD;
&#xD;
          -  Have permanent lip implant, and lip enhancement or laser therapy performed within the&#xD;
             preceding 12 months;&#xD;
&#xD;
          -  Known history of allergy or sensitivity to glycerol, Tegaderm, lidocaine, hyaluronic&#xD;
             acid dermal fillers or materials with gram-positive bacterial proteins.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dieter Manstein, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Neera Nathan, MD, MSHS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lais Clinical Research Coordinator</last_name>
    <phone>(617) 726-4454</phone>
    <email>lgomes@mgh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Neera Nathan, MD</last_name>
    <email>nnathan2@mgh.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MGH Clinical Unit for Research Trials &amp; Outcomes Research</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lais Gomes</last_name>
      <email>lgomes@mgh.harvard.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.galderma.com/us/sites/g/files/jcdfhc341/files/2020-04/Restylane_Kysse-Patient_Brochure.pdf?_ga=2.59052845.1698235642.1604334264-853585669.1604334264&amp;_gac=1.157524424.1604378565.CjwKCAiA-f78BRBbEiwATKRRBPyH8_64L0BLjGEHNISljih9I6tz-fSQohCtDMdwKAe7hz57dYQAihoCieQQAvD_BwE</url>
    <description>Restylane Kysse Patient Brochure</description>
  </link>
  <reference>
    <citation>Uitto J. Understanding premature skin aging. N Engl J Med. 1997 Nov 13;337(20):1463-5.</citation>
    <PMID>9358147</PMID>
  </reference>
  <reference>
    <citation>Zouboulis ChC. [Intrinsic skin aging. A critical appraisal of the role of hormones]. Hautarzt. 2003 Sep;54(9):825-32. German.</citation>
    <PMID>12955259</PMID>
  </reference>
  <reference>
    <citation>Leung WC, Harvey I. Is skin ageing in the elderly caused by sun exposure or smoking? Br J Dermatol. 2002 Dec;147(6):1187-91.</citation>
    <PMID>12452869</PMID>
  </reference>
  <reference>
    <citation>Argyropoulos AJ, Robichaud P, Balimunkwe RM, Fisher GJ, Hammerberg C, Yan Y, Quan T. Alterations of Dermal Connective Tissue Collagen in Diabetes: Molecular Basis of Aged-Appearing Skin. PLoS One. 2016 Apr 22;11(4):e0153806. doi: 10.1371/journal.pone.0153806. eCollection 2016.</citation>
    <PMID>27104752</PMID>
  </reference>
  <reference>
    <citation>van Waateringe RP, Mook-Kanamori MJ, Slagter SN, van der Klauw MM, van Vliet-Ostaptchouk JV, Graaff R, Lutgers HL, Suhre K, El-Din Selim MM, Mook-Kanamori DO, Wolffenbuttel BHR. The association between various smoking behaviors, cotinine biomarkers and skin autofluorescence, a marker for advanced glycation end product accumulation. PLoS One. 2017 Jun 20;12(6):e0179330. doi: 10.1371/journal.pone.0179330. eCollection 2017.</citation>
    <PMID>28632785</PMID>
  </reference>
  <reference>
    <citation>Gilchrest BA, Soter NA, Hawk JL, Barr RM, Black AK, Hensby CN, Mallet AI, Greaves MW, Parrish JA. Histologic changes associated with ultraviolet A--induced erythema in normal human skin. J Am Acad Dermatol. 1983 Aug;9(2):213-9.</citation>
    <PMID>6886112</PMID>
  </reference>
  <reference>
    <citation>Rogers GS, Gilchrest BA. The senile epidermis: environmental influences on skin ageing and cutaneous carcinogenesis. Br J Dermatol. 1990 Apr;122 Suppl 35:55-60. Review.</citation>
    <PMID>2186787</PMID>
  </reference>
  <reference>
    <citation>Bentov I, Reed MJ. The effect of aging on the cutaneous microvasculature. Microvasc Res. 2015 Jul;100:25-31. doi: 10.1016/j.mvr.2015.04.004. Epub 2015 Apr 24. Review.</citation>
    <PMID>25917013</PMID>
  </reference>
  <reference>
    <citation>Tamura E, Ishikawa J, Sugata K, Tsukahara K, Yasumori H, Yamamoto T. Age-related differences in the functional properties of lips compared with skin. Skin Res Technol. 2018 Aug;24(3):472-478. doi: 10.1111/srt.12456. Epub 2018 Feb 6.</citation>
    <PMID>29405429</PMID>
  </reference>
  <reference>
    <citation>Hilton S, Sattler G, Berg AK, Samuelson U, Wong C. Randomized, Evaluator-Blinded Study Comparing Safety and Effect of Two Hyaluronic Acid Gels for Lips Enhancement. Dermatol Surg. 2018 Feb;44(2):261-269. doi: 10.1097/DSS.0000000000001282.</citation>
    <PMID>29059146</PMID>
  </reference>
  <reference>
    <citation>Stojanovič L, Majdič N. Effectiveness and safety of hyaluronic acid fillers used to enhance overall lip fullness: A systematic review of clinical studies. J Cosmet Dermatol. 2019 Apr;18(2):436-443. doi: 10.1111/jocd.12861. Epub 2019 Jan 12.</citation>
    <PMID>30636365</PMID>
  </reference>
  <reference>
    <citation>Savoia A, Accardo C, Vannini F, Di Pasquale B, Baldi A. Outcomes in thread lift for facial rejuvenation: a study performed with happy lift™ revitalizing. Dermatol Ther (Heidelb). 2014 Jun;4(1):103-14. doi: 10.1007/s13555-014-0041-6. Epub 2014 Jan 17.</citation>
    <PMID>24436079</PMID>
  </reference>
  <reference>
    <citation>Carruthers A, Carruthers J, Hardas B, Kaur M, Goertelmeyer R, Jones D, Rzany B, Cohen J, Kerscher M, Flynn TC, Maas C, Sattler G, Gebauer A, Pooth R, McClure K, Simone-Korbel U, Buchner L. A validated lip fullness grading scale. Dermatol Surg. 2008 Nov;34 Suppl 2:S161-6. doi: 10.1111/j.1524-4725.2008.34365.x.</citation>
    <PMID>19021674</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 25, 2021</study_first_submitted>
  <study_first_submitted_qc>April 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2021</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Dieter Manstein, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to make individual participant data (IPD) available to other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

